Skip to content
Medical Health Aged Care

New report on Australia’s health reinforces need for increased investment in dementia services, awareness raising and brain health promotion

Dementia Australia 2 mins read

Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 as reported by the Australian Institute of Health and Welfare (AIHW) in Australia’s Health 2024 publication released today.

Dementia Australia CEO Professor Tanya Buchanan said the report reinforces the enormity and impact of dementia in Australia as the chronic disease of the 21st century and must receive the attention it needs.

“The report provides vital information for governments, and the health, aged care and disability sectors to ensure there is investment in appropriate dementia supports and services,” Professor Buchanan said.
 
“The data also provides compelling evidence of the need for further funding commitments to dementia research, increasing community awareness and a strategic public health approach to dementia prevention.
 
“The latest research tells us that with increased awareness of the modifiable risk factors across populations and over time, we could be delaying or potentially preventing 40 per cent of dementia cases.
 
“With the number of people with dementia expected to double by 2054, we need a National Dementia Action Plan to provide a clear vision for the future to move dementia care forward in Australia.   
 
“Dementia Australia and people living with dementia, their families and carers have contributed to the development of the next iteration of the draft National Dementia Action Plan and we eagerly await its release.
 
“With more than 421,000 people living with dementia in Australia, and more than 1.6 million people involved in their care it is essential that all Australians know that no matter who you are or how you’re affected by dementia, Dementia Australia is here for you. 
 
“I encourage anyone with any questions or concerns to contact the National Dementia Helpline on 1800 100 500, 24 hours a day, seven days a week or visit dementia.org.au.” 

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Gabrielle Prabhu, Media & Communications Manager, 0447 253 583 or Gabrielle.Prabhu@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 17/02/2025
  • 15:07
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New ZealandGynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the…

  • Contains:
  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

  • Medical Health Aged Care
  • 17/02/2025
  • 10:11
Smith & Nephew UK Ltd

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair*After anchor insertionSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.